Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $23.6252W HIGH $29.21
Volume
44.43 M
Value Traded
1.34 B
Short % Float
2.73%
+0.07%Week
+0.14%1 Month
+15.1%3 Month
+3.34%6 Month
-35.59%5 Year
+5,929.79%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
158.56 B
EPS (TTM)
0.76
P/E Ratio
36.60
Ent. Value
209.97 B
Total Shares
5.70 B
Float Shares
5.69 B
Insiders
0.09%
Institutions
69.80%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PFE Catalyst Timeline
Dated clinical, regulatory and corporate events for Pfizer, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pfizer, Inc.
421Total events
55Upcoming
186Tier-1 (high impact)
2014 to 2031Coverage
Upcoming catalysts 2
Event history 50
▲FDA ApprovalTUKYSAApprovedFDA Decision
FDA approves TUKYSA + trastuzumab + pertuzumab as front-line maintenance for HER2+ metastatic breast cancer
HER2+ metastatic breast cancer (front-line maintenance)source ↗
▲Corporate ApprovalCorporate
Pfizer board declares fourth-quarter 2026 dividend of $0.43 per share
▲Topline ReadoutRitlecitinibApprovedClinical Data
LITFULO 100 mg met co-primary endpoints in TRANQUILLO 2 at Week 52
nonsegmental vitiligosource ↗
▲Oral PresentationRitlecitinibApprovedPresentation
Late-breaking oral presentation of TRANQUILLO 2 and TRANQUILLO results at EADV 2026
nonsegmental vitiligosource ↗
●Additional DataCibinqoApprovedClinical Data
Late-breaking exploratory serum protein biomarker analysis from JADE COMPARE
atopic dermatitissource ↗
●Safety Data UpdateCibinqoApprovedClinical Data
Final integrated safety analysis of CIBINQO in 3,850 patients with up to 6.5 years exposure
atopic dermatitissource ↗
▲Primary Endpoint MetRitlecitinibApprovedClinical Data
TRANQUILLO 2 co-primary endpoints met
nonsegmental vitiligosource ↗
●Interim Efficacy DatatilrekimigClinical Data
Interim Phase 2 Week 16 efficacy and safety results for tilrekimig (PF-07275315)
atopic dermatitissource ↗
▲Long Term DataRitlecitinibApprovedClinical Data
Long-term Phase 3 data showing scalp hair regrowth with LITFULO through five years
alopecia areatasource ↗
▲Oral PresentationtilrekimigPresentation
Detailed Phase 2 results presented in oral presentation at EADV Annual Congress
moderate-to-severe atopic dermatitissource ↗
▲Safety Data UpdatetilrekimigClinical Data
Safety data from Phase 2 study showing tilrekimig well-tolerated
moderate-to-severe atopic dermatitissource ↗
▲Primary Endpoint MettilrekimigClinical Data
Phase 2 study met primary endpoint of EASI-75 at Week 16 in atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
▲Secondary Endpoint DatatilrekimigClinical Data
Key secondary endpoint vIGA 0/1 results at Week 16
moderate-to-severe atopic dermatitissource ↗
▲Additional DatatilrekimigClinical Data
Exploratory PP-NRS4 itch reduction analysis
moderate-to-severe atopic dermatitissource ↗
●Management ChangeCorporate
Professor Bill Sessa appointed Chair of Isomab's Scientific Advisory Board
▲Supplemental ApprovalComirnatyApprovedFDA Decision
FDA approved sBLA for COMIRNATY XFG-adapted COVID-19 vaccine
COVID-19source ↗
▲Product LaunchComirnatyApprovedPost-Market
Shipping of 2026-2027 COVID-19 vaccine begins immediately
COVID-19source ↗
●IP Litigation RulingProveraApprovedIP / Competition
Court issues case-management order noting settlement
intracranial meningiomassource ↗
▲Topline ReadoutHYMPAVZIApprovedClinical Data
Positive topline results from Phase 3 BASIS study
hemophilia A or B with inhibitorssource ↗
▲Primary Endpoint MetHYMPAVZIApprovedClinical Data
Primary endpoint met in BASIS study
hemophilia A or B with inhibitorssource ↗
▲Topline ReadoutRitlecitinibApprovedClinical Data
Positive topline Phase 3 results for LITFULO in nonsegmental vitiligo (TRANQUILLO 2)
nonsegmental vitiligosource ↗
▲Primary Endpoint MetRitlecitinibApprovedClinical Data
TRANQUILLO met co-primary endpoints (F-VASI75 and T-VASI50 at Week 52)
nonsegmental vitiligosource ↗
●Safety Data UpdateRitlecitinibApprovedClinical Data
Safety profile consistent with alopecia areata; no new safety signals in NSV
nonsegmental vitiligosource ↗
▲CHMP Positive OpinionEx-US Regulatory
CHMP recommends marketing authorization for LP.8.1-adapted monovalent COVID-19 vaccine
COVID-19source ↗
▲CHMP Positive OpinionCOMIRNATY®LP.8.1Ex-US Regulatory
CHMP recommended marketing authorization for LP.8.1-adapted COVID-19 vaccine
COVID-19source ↗
▲EU ApprovalComirnatyApprovedEx-US Regulatory
European Commission grants marketing authorization for XFG-adapted COVID-19 vaccine
COVID-19 preventionsource ↗
▲CHMP Positive OpinionComirnatyApprovedEx-US Regulatory
CHMP recommends XFG-adapted COVID-19 vaccine
COVID-19 preventionsource ↗
▲FDA Filing AcceptedTALZENNAApprovedRegulatory Filing
FDA accepted sNDA for TALZENNA plus XTANDI for mCSPC
HRR gene-mutated metastatic castration-sensitive prostate cancersource ↗
▲Partnership / LicenseCorporate
Bluesight and Pfizer partner to integrate SmartDose RFID-enabled medications with KitCheck
●IP Litigation RulingProveraApprovedIP / Competition
Pfizer enters settlement program for Depo-Provera litigation
intracranial meningiomassource ↗
▲FDA ApprovalPADCEVApprovedFDA Decision
FDA approves PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer
muscle-invasive bladder cancersource ↗
▲FDA ApprovalPalbociclibApprovedFDA Decision
FDA approves IBRANCE regimen for HR+, HER2+ metastatic breast cancer frontline maintenance
HR+, HER2+ metastatic breast cancer frontline maintenancesource ↗
●PublicationPresentation
Landmark publication demonstrating clinical PK predictions using multi-tissue chip platform
◆Topline Readoutsigvotatug vedotinClinical Data
Topline Phase 3 results for Sigvotatug Vedotin
previously treated metastatic non-squamous non-small cell lung cancersource ↗
▲Label ExpansionHYMPAVZIApprovedFDA Decision
FDA approves expanded indication for HYMPAVZI to include hemophilia A or B patients with inhibitors and pediatric patients
hemophilia A or B with inhibitors (12+ years) and pediatric (6-11 years) with or without inhibitorssource ↗
▲Topline ReadoutBerobenatideClinical Data
Phase 2b topline results for Berobenatide in obesity
obesitysource ↗
◆Oral PresentationPF'3944Presentation
Detailed results from VESPER-3 to be presented at ADA 86th Scientific Sessions
obesity or overweight without type 2 diabetessource ↗
◆Oral PresentationTUKYSAApprovedPresentation
Efficacy and safety of tucatinib plus trastuzumab and pertuzumab as maintenance therapy by subgroups
HER2+ metastatic breast cancersource ↗
▲Oral PresentationTALZENNAApprovedPresentation
Late-breaking oral presentation of TALAPRO-3 results at ASCO 2026
metastatic castration-sensitive prostate cancer (mCSPC) with HRR gene mutationssource ↗
▲Primary Endpoint MetTALZENNAApprovedClinical Data
TALAPRO-3 met primary endpoint of rPFS
metastatic castration-sensitive prostate cancer (mCSPC) with HRR gene mutationssource ↗
▲Full ResultsTALZENNAApprovedClinical Data
Simultaneous publication of TALAPRO-3 results in New England Journal of Medicine
metastatic castration-sensitive prostate cancer (mCSPC) with HRR gene mutationssource ↗
▲Interim AnalysisTALZENNAApprovedTrial
Interim overall survival analysis shows strong trend
metastatic castration-sensitive prostate cancer (mCSPC) with HRR gene mutationssource ↗
◆Poster PresentationPF-07220060Presentation
Neoadjuvant atirmociclib plus letrozole vs letrozole alone: results from FOURLIGHT-2
HR+/HER2- breast cancersource ↗
◆Poster PresentationTUKYSAApprovedPresentation
In-depth safety analysis of tucatinib plus trastuzumab and pertuzumab as first-line maintenance
HER2+ metastatic breast cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How PFE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-24 | Ibrance (palbociclib) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A87 / 100
Pipeline Score
$55.3B
Pipeline Value
$284.1B
Commercial Value
Undervalued
Valuation Signal
196
Drugs Scored
1.2x
rNPV / MCap
Top 1%
Large Pharma(rank 8 of 658)
Percentile Rank
Pfizer, Inc. earns an A-grade pipeline score (87/100), with $55.3B risk-adjusted pipeline value, led by ibuzatrelvir in COVID-19 SARS-CoV-2 Infection (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $63.7B x 4.5 = $284.1B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Eliquis | $8.6B | $7.4B | +17% |
| Vyndaqel | $6.6B | $6.1B | +9% |
| Prevnar family | $6.5B | $6.4B | +1.2% |
| Ibrance | $4.2B | $4.2B | -1.1% |
| Comirnaty | $3.9B | $5.8B | -31.9% |
| Padcev | $2.2B | $1.8B | +22.6% |
| Xtandi | $2.1B | $2.1B | 0% |
| Paxlovid, EUA-Labeled | $1.7B | $4.3B | -62% |
| Nurtec ODT/Vydura | $1.6B | $1.3B | +19% |
| Lorbrena | $1.2B | $872M | +38.6% |
| Abrysvo | $1.1B | $828M | +38.5% |
| Xeljanz | $1.1B | $1.1B | -4.7% |
Top 12 of 30 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ibuzatrelvir Small moleculeNCT06679140 | COVID-19 SARS-CoV-2 Infection | Phase 3 | RECRUITING | 2,330 | Feb 12, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every PFE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LITFULO | nonsegmental vitiligo | Phase 3 | 2026-10-02 | significant improvements in facial and total body repigmentationRead More | Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental VitiligoRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BOURLA ALBERTDirector, Officer (Chairman & CEO) | Buy | 38,000 429,173 held | $26.34 | 08/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PFE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0.6 % (-64.7 %) | 3.26 M | 135.37 K | -37.04% ( -79.63 K) |
PFE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-27 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PFE ranks across every disease it competes in
Competitive Position is a premium feature
See how PFE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPFE News
PFE▼ -0.7%today
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
Pfizer has received FDA approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab. This approval allows the drug to be used as a maintenance treatment for adults with unresectable locally advanced or metastatic HER2+ breast cancer following induction therapy. This marks a significant advancement in treatment options for patients at an earlier stage of metastatic disease.
Read more →PFE▼ -0.7%today
Pfizer Declares Fourth-Quarter 2026 Dividend
Pfizer Inc. has declared a $0.43 dividend for the fourth quarter of 2026, payable on December 7, 2026. This decision reflects the company's ongoing commitment to its capital allocation strategy, aiming to maintain and grow dividends over time. The upcoming dividend will be the 352nd consecutive payment to shareholders.
Read more →PFEPfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
Pfizer Inc. presented positive results from two Phase 3 trials for LITFULO (ritlecitinib), demonstrating significant improvements in facial and total body repigmentation in patients with nonsegmental vitiligo. The trials, TRANQUILLO 2 and TRANQUILLO, showed that both 100 mg and 50 mg dosages outperformed placebo. Patient-reported outcomes further supported these findings, indicating reduced disease severity.
Read more →PFEPfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
Pfizer presented positive results from a Phase 2 study of tilrekimig for atopic dermatitis. The study achieved its primary endpoint, showing a significant increase in skin clearance among participants. This was measured by the Eczema Area and Severity Index at Week 16, indicating promising efficacy for the treatment.
Read more →PFEProfessor Bill Sessa, Former Chief Scientific Officer of Internal Medicine at Pfizer, Appointed Chair of Isomab's Scientific Advisory Board
Isomab Ltd has appointed Professor Bill Sessa as Chair of its Scientific Advisory Board. He will lead a team of distinguished vascular biologists as the company advances its first-in-class anti-VEGF-A165b antibody, ISM-001, towards clinical trials for chronic angina. This strategic move aims to enhance the development of novel therapies for patients with cardiovascular diseases.
Read more →PFEPfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
Pfizer Inc. will present 45 research abstracts at the upcoming ESMO Congress in Madrid. The presentations will include 11 oral presentations highlighting advancements in cancer treatments, particularly in breast, genitourinary, and lung cancers. This event underscores Pfizer's commitment to enhancing cancer care and exploring future breakthroughs.
Read more →PFEPfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
Pfizer Inc. has announced a conference call scheduled for November 3, 2026, at 10:00 a.m. EST. The call aims to update investors on the company's third quarter performance. Participants can access the webcast and the performance report through Pfizer's investor website.
Read more →PFEHealth Canada Authorizes Pfizer and BioNTech's Omicron XFG-Adapted COVID-19 Vaccine
Health Canada has authorized Pfizer and BioNTech's updated COMIRNATY vaccine for individuals aged 6 months and older, specifically targeting the Omicron XFG variant. This approval is based on extensive clinical and real-world data demonstrating the vaccine's safety and effectiveness. Pfizer Canada has ensured adequate inventory for vaccination programs across Canada, emphasizing the importance of vaccination in combating COVID-19.
Read more →PFEPfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. is inviting the public and investors to listen to a webcast featuring Alexandre de Germay, the Chief International Commercial Officer, at the J.P. Morgan U.S. All Stars 2026 Conference. The event is scheduled for September 22, 2026, at 11:50 a.m. BST. Details for accessing the webcast can be found on Pfizer's investor website.
Read more →PFEPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
Pfizer and BioNTech have received FDA approval for their 2026-2027 COVID-19 vaccine, which targets the XFG variant. The vaccine is intended for adults aged 65 and older, as well as younger individuals with underlying health conditions. Shipping of the vaccine will commence immediately to ensure timely access. The approval is based on comprehensive data demonstrating the vaccine's effectiveness against various SARS-CoV-2 variants.
Read more →PFELegal Bay Pre-Settlement Funding Reports Pfizer Agrees to Settle Depo-Provera Birth Control Litigation
Pfizer has agreed to a settlement program to resolve a substantial number of lawsuits alleging that Depo-Provera caused intracranial meningiomas. Legal Bay estimates that around 5,000 claims could settle for over $1.2 billion. The financial terms remain confidential, and actual compensation will depend on various factors. The settlement is seen as a significant development for affected claimants.
Read more →PFEPfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Pfizer and Valneva announced that the European Medicines Agency has validated their Marketing Authorization Application for PF-07307405, a Lyme disease vaccine candidate. This application is based on positive results from the Phase 3 VALOR trial, which demonstrated over 70% efficacy. The vaccine was well tolerated, with no safety issues reported, marking a significant step in addressing Lyme disease in Europe.
Read more →PFEPfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
Pfizer Inc. reported its second-quarter financial results for 2026, showcasing a strong performance. The company raised its full-year revenue guidance by $500 million at the midpoint while reaffirming its adjusted diluted EPS guidance. CEO Dr. Albert Bourla highlighted the company's commitment to delivering on financial expectations.
Read more →PFEPfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
Pfizer has reported positive topline results from two Phase 3 trials of LITFULO for treating nonsegmental vitiligo. The trials assessed the drug's efficacy and safety in patients with varying disease severity. Both studies showed significant results for the 50 and 100 milligram doses, indicating a promising treatment option.
Read more →PFEEuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
Pfizer and BioNTech have received marketing authorization from the European Commission for their COVID-19 vaccine targeting the XFG variant. This new formulation is approved for active immunization in individuals aged 6 months and older. The authorization follows recommendations from the European Medicines Agency's Emergency Task Force.
Read more →PFEFDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
Pfizer announced that the FDA has accepted for Priority Review a supplemental New Drug Application for TALZENNA in combination with XTANDI. This treatment is aimed at men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer. The Priority Review designation may accelerate the approval timeline for this therapy.
Read more →PFEBluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies
Bluesight has partnered with Pfizer to integrate SmartDose RFID-enabled medications with the KitCheck inventory management platform. This collaboration aims to streamline hospital workflows by providing pre-tagged medications, enhancing efficiency and patient safety. SmartDose medications are expected to be available for purchase in the second half of 2026.
Read more →PFEU.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizer and Astellas announced FDA approval for PADCEV combined with Keytruda as a treatment for muscle-invasive bladder cancer. This approval allows for neoadjuvant and adjuvant therapy in adult patients, irrespective of their eligibility for cisplatin. This marks a significant advancement in treatment options for this patient population.
Read more →PFEBenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board
BenchSci has appointed Dr. Mikael Dolsten as its first Chairman of the Board, effective June 2026. Dr. Dolsten, who previously served as Chief Scientific Officer at Pfizer, joined the board as a director in July 2025. His extensive experience in biopharma research is expected to guide BenchSci's future developments.
Read more →About Pfizer, Inc.
Headquarters66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192
BIOPHARMAWATCH ELITE PLUS
Trade the next PFE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime